Evaluation of the rationality of the drug promotional literature distributed among the physicians using the W.H.O guidelines
European Journal of Molecular & Clinical Medicine,
2022, Volume 9, Issue 3, Pages 2831-2836
AbstractBackground:One of the key elements for the marketing of drugs and especially the new ones that are entering the market undertaken by the various pharmaceuticals industries is the use of drug promotional literature.
Material and Methods:A total of 300 DPLs were assessed for their completeness according to the W.H.O criteria.
Results: A total of 300 DPLs were analysed out of which 66% (198) of the total DPLs promoted a single drug and 34% (102) DPLs were FDCs. Most of the DPLs were related to the drugs acting on the cardiovascular system (17.33%). Upon assessing the DPLs in accordance with the W.H.O criteria it was found that 95.67% (287) DPLs had the International non-proprietary name (INN) mentioned in them while 100% (300) DPLs had the brand name written on them. The active dosage form of the drug was mentioned in 95.67% (287) DPLs. Most of them published the dosage form [98% (294)], name and address of the manufacturer or distributor [97.66% (293)].the excipients were mentioned in only 4.67% (14), precautions and warnings in 42.67% (128), contraindications to the use of medications in 46.33% (139), major drug interactions in 41.67% (125), address of the manufacturer or distributor in 65.33% (196).
Conclusion:The pharmaceutical companies are trying to meet the requirements as laid down by the WHO for drug promotional literature but still some regions remain an area of concern.
- Article View: 4
- PDF Download: 12